Pharmacology and in vitro profiling of a novel peroxisome proliferator-activated receptor γ ligand, Cerco-A.

Peroxisome proliferator-activated receptor γ (PPARγ; NR1C3) is known as a key regulator of adipocytogenesis and the molecular target of thiazolidinediones (TZDs), also known as antidiabetic agents. Despite the clinical benefits of TZDs, their use is often associated with adverse effects including peripheral edema, congestive heart failure, and weight gain. Here we report the identification and characterization of a non-thiazolidinedione PPARγ partial agonist, Cerco-A, which is a derivative of the natural product, (-)-cercosporamide. Cerco-A was found to be a binder of the PPARγ ligand-binding domain in a ligand competitive binding assay and showed a unique cofactor recruitment profile compared to rosiglitazone. A crystal structure analysis revealed that Cerco-A binds to PPARγ without direct hydrogen bonding to helix12. In PPARγ transcriptional activation assay and an adipocyte differentiation assay, Cerco-A was a potent partial agonist of PPARγ. After a 14-day oral administration, once per day of Cerco-A in Zucker diabetic fatty (ZDF) rats, an apparent decrease of plasma glucose and triglyceride was observed, as with pioglitazone. To evaluate drug safety, Cerco-A was administered for 13 days orally in non-diabetic Zucker fatty (ZF) rats. Each of the hemodilution parameters (hematocrit, red blood cells number, and hemoglobin), which are considered as undesirable effects of TZDs, was improved significantly compared to pioglitazone. While Cerco-A showed body weight gain, as with pioglitazone, Cerco-A had significantly lower effects on heart and white adipose tissues weight gain. The results suggest that Cerco-A offers beneficial effects on glycemic control with attenuated undesirable side effects.

[1]  I. Kawamura,et al.  Mechanism by which a novel non‐thiazolidinedione peroxisome proliferator‐activated receptor γ agonist, FK614, ameliorates insulin resistance in Zucker fatty rats , 2007, Diabetes, obesity & metabolism.

[2]  K. Wakabayashi,et al.  Discovery of a novel selective PPARgamma modulator from (-)-Cercosporamide derivatives. , 2010, Bioorganic & medicinal chemistry letters.

[3]  M. Lindstrom,et al.  INT131: A Selective Modulator of PPARγ , 2009 .

[4]  B. Zinman,et al.  Rosiglitazone-Associated Fractures in Type 2 Diabetes , 2008, Diabetes Care.

[5]  Mi-kyung Kim,et al.  PAR-1622 is a selective peroxisome proliferator-activated receptor γ partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention , 2009, Archives of pharmacal research.

[6]  Dorothy D. Sears,et al.  MBX-102/JNJ39659100, a novel peroxisome proliferator-activated receptor-ligand with weak transactivation activity retains antidiabetic properties in the absence of weight gain and edema. , 2009, Molecular endocrinology.

[7]  I. Kawamura,et al.  Ameliorating effect of FK614, a novel nonthiazolidinedione peroxisome proliferator-activated receptor gamma agonist, on insulin resistance in Zucker fatty rat. , 2005, European journal of pharmacology.

[8]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[9]  S. O’Rahilly,et al.  PPARγ and human metabolic disease , 2006 .

[10]  Margaret S. Wu,et al.  A novel selective peroxisome proliferator-activator receptor-gamma modulator-SPPARgammaM5 improves insulin sensitivity with diminished adverse cardiovascular effects. , 2008, European journal of pharmacology.

[11]  M. Lindstrom,et al.  T2384, a Novel Antidiabetic Agent with Unique Peroxisome Proliferator-activated Receptor γ Binding Properties* , 2008, Journal of Biological Chemistry.

[12]  R. Evans,et al.  Nuclear receptors and lipid physiology: opening the X-files. , 2001, Science.

[13]  C. Mantzoros,et al.  The Development of INT131 as a Selective PPARγ Modulator: Approach to a Safer Insulin Sensitizer , 2008, PPAR research.

[14]  J. Berger,et al.  Physiological and therapeutic roles of peroxisome proliferator-activated receptors. , 2002, Diabetes technology & therapeutics.

[15]  Scott A. Busby,et al.  Partial agonists activate PPARgamma using a helix 12 independent mechanism. , 2007, Structure.

[16]  A. Werner,et al.  A Review of Rosiglitazone in Type 2 Diabetes Mellitus , 2001, Pharmacotherapy.

[17]  F. Gregoire,et al.  Cross-Species Differential Plasma Protein Binding of MBX-102/JNJ39659100: A Novel PPAR-γ Agonist , 2008, PPAR research.

[18]  K. King,et al.  Prevalence of edema in patients receiving combination therapy with insulin and thiazolidinedione. , 2004, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[19]  T. Fujimura,et al.  Unique properties of coactivator recruitment caused by differential binding of FK614, an anti-diabetic agent, to peroxisome proliferator-activated receptor gamma. , 2006, Biological & pharmaceutical bulletin.

[20]  S. Grundy,et al.  Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. , 2003, Circulation.

[21]  I. Kawamura,et al.  Pharmacological characteristics of a novel nonthiazolidinedione insulin sensitizer, FK614. , 2004, European journal of pharmacology.

[22]  Nancee V. Niemeyer,et al.  Thiazolidinedione‐Induced Edema , 2002, Pharmacotherapy.

[23]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[24]  B. Lowell.  An Essential Regulator of Adipogenesis and Modulator of Fat Cell Function: PPARγ , 1999, Cell.

[25]  J. Zou,et al.  Improved methods for building protein models in electron density maps and the location of errors in these models. , 1991, Acta crystallographica. Section A, Foundations of crystallography.

[26]  T. Willson,et al.  Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ , 1998, Nature.

[27]  B. Spiegelman,et al.  PPARγ: a Nuclear Regulator of Metabolism, Differentiation, and Cell Growth* , 2001, The Journal of Biological Chemistry.

[28]  J. Ohsumi,et al.  (-)-Cercosporamide derivatives as novel antihyperglycemic agents. , 2009, Bioorganic & medicinal chemistry letters.

[29]  I. Issemann,et al.  The mouse peroxisome proliferator activated receptor recognizes a response element in the 5′ flanking sequence of the rat acyl CoA oxidase gene. , 1992, The EMBO journal.

[30]  T. Willson,et al.  Identification of a Bile Acid-responsive Element in the Human Ileal Bile Acid-binding Protein Gene , 1999, The Journal of Biological Chemistry.

[31]  T. Fujimura,et al.  FK614, a novel peroxisome proliferator-activated receptor gamma modulator, induces differential transactivation through a unique ligand-specific interaction with transcriptional coactivators. , 2005, Journal of pharmacological sciences.

[32]  J. Flier,et al.  Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. , 1997, The Journal of biological chemistry.